Unwanted immune responses against protein therapeutics can reduce efficacy or lead to adverse reactions. T-cell responses are key in the development of such responses, and are directed against immunodominant regions within the protein sequence, often associated with binding to several allelic variants of HLA class II molecules (promiscuous binders). Herein, we report a novel computational strategy to predict 'de-immunized' peptides, based on previous studies of erythropoietin protein immunogenicity. This algorithm (or method) first predicts promiscuous binding regions within the target protein sequence and then identifies residue substitutions predicted to reduce HLA binding. Further, this method anticipates the effect of any given substitution on flanking peptides, thereby circumventing the creation of nascent HLAbinding regions. As a proof-of-principle, the algorithm was applied to Vatreptacog a, an engineered Factor VII molecule associated with unintended immunogenicity. The algorithm correctly predicted the two immunogenic peptides containing the engineered residues. As a further validation, we selected and evaluated the immunogenicity of seven substitutions predicted to simultaneously reduce HLA binding for both peptides, five control substitutions with no predicted reduction in HLAbinding capacity, and additional flanking region controls. In vitro immunogenicity was detected in 21Á4% of the cultures of peptides predicted to have reduced HLA binding and 11Á4% of the flanking regions, compared with 46% for the cultures of the peptides predicted to be immunogenic. This method has been implemented as an interactive application, freely available online at http://tools.iedb.org/deimmu nization/.
Introduction
Native and engineered proteins are widely used as drugs to treat a variety of different ailments. One of the issues often encountered in their use is that proteins, whether of self or non-self origin, are often associated with some degree of potential immunogenicity. This immunogenicity, in turn, may be associated with decreased efficacy and/or potential safety issues. Accordingly, developing the capacity to predict potential immunogenicity, affording strategies to decrease the potential immunogenicity of protein drugs, has been the subject of intense investigation. 
I M M U N O L O G Y O R I G I N A L A R T I C L E
groups, including De Groot and co-workers, have worked on this subject and produced valuable contributions. [26] [27] [28] [29] Several different variables affect protein immunogenicity, including their propensity to form aggregates, the degree of difference from self, uptake by antigen-presenting cells and, as it is well established that HLA class II binding is a necessary (although not sufficient) condition for T-cell immunogenicity, their content in terms of HLA-binding epitopes. CD4 T-cell responses are mediated by HLA class II molecules and are involved in responses to exogenously administered proteins. For this reason, HLA class II binding is a particularly relevant variable in the context of protein immunogenicity. 30 Several methodologies are available to measure and predict HLA binding, as reviewed elsewhere. 31, 32 Prominent among the various approaches is the direct measurement of peptide-binding capacity using purified HLA molecules in quantitative assays, and prediction of binding using matrix, neural network and machine-learning algorithms. 33 Relatively few studies have defined the thresholds of measured or predicted binding associated with immunogenicity for class I 34, 35 or more relevant to the current study, for certain HLA class II alleles. [36] [37] [38] [39] In the clinical setting, the application of methodologies to predict and reduce immunogenicity based on HLAbinding requires the development and validation of strategies to address HLA heterogeneity. HLA class II molecules are encoded by four main loci, namely DRB1, DRB3/4/5, DQ and DP, and each locus is polymorphic. Thousands of different HLA variants exist, and this high degree of diversity is reflected in most human populations in general, and patient populations in particular. 40 In a series of different studies we showed that HLA molecules encoded by each of these loci often have a significant degree of overlap, both inter-locus and intra-locus, in terms of their peptide-binding repertoire. Indeed, unbiased clustering analysis showed that HLA class II can be grouped into several main supertypic binding specificities. [41] [42] [43] Peptide epitopes binding multiple HLA alleles (promiscuous epitopes) account for most responses in the general population. [44] [45] [46] [47] [48] We have previously shown that focusing on a subset of 46 HLA class II molecules most represented in the general population worldwide allows us to account for about 90% of HLA variants expressed. 49 We further showed that a subset of 27 alleles also allows for covering a substantial majority of HLA molecules. 41 Further, a method based on calculating the median HLA binding for a set of seven prototype alleles (the '7-allele method') was shown to be effective in predicting immunogenicity on a population level. 50 Here we evaluate different methods to predict reduced immunogenicity, describe the implementation of a methodology to select among different modifications, and provide a freely available online tool to accomplish this goal.
Materials and methods

Training data set
The training data set was extracted from a previously published erythropoietin (EPO) de-immunization study. 51 In that study, 15mer peptides with a 10-residue overlap were generated from EPO and tested in five donors. Based on interleukin-2 (IL-2) ELISPOT assays and binding affinities to 15 selected alleles, two regions were identified as highly immunogenic. Different amino acid substitutions were applied to these regions and peptides with minimum immunogenicity were selected. Accordingly, the EPO data set consists of two groups of peptides. The first set pertains to the identification of immunogenic regions in the protein, and includes 31 peptides (15mers) spanning the entire EPO sequence. Of these 31 peptides, four were immunogenic in ≥ 50% of the donors. These four peptides span two regions, encompassing residues 91-120 (region 1) and 136-150 (region 2).
A second set of peptides pertains to the selection of non-immunogenic variants, where Tangri et al. probed the capacity of 12 analogues of region 1 (targeting positions 101-115) and nine analogues from region 2 (targeting position 16-150) to confer reduced immunogenicity. 51 The sequence and immunogenicity of each analogue can be found in Table 1 .
Prediction approach selection
We applied Immune Epitope Database (IEDB) -recommended (consensus, see ref. 52) methods to predict HLA class II binding capacity for three different sets of alleles: (i) the same 15 alleles described in the EPO paper, 51 (ii) the seven-allele subset described by Paul et al. 50 and (iii) the 26 most common and/or representative alleles, 41 referred as 26-allele method throughout this manuscript. The seven-allele method predicts immunogenicity based on the median centile predicted binding of seven alleles representative of the binding motifs most commonly recognized in the general human population.
Performance evaluation parameters
Performance of the different prediction approaches was evaluated calculating Matthew's correlation coefficient (MCC) and the area under the receiver operating characteristics curve (AUC) and the following parameters:
TP Specificity, ratio of correct predictions in immunogenic peptides Accuracy, ratio of correct predictions in immunogenic and non-immunogenic peptides.
Development of an online tool
Python scripts for an automated pipeline were divided into two parts, where the first part selects predicted promiscuous binding regions in a protein and the second part applies and evaluates the predicted effect of various amino acid substitutions on the selected region/peptide (s). The scripts were written and implemented using the DJANGO platform (https://www.djangoproject.com/).
Experimental validation
For experimental validation we selected the Recombinant factor VIIa (Vatreptacog a) protein, where three mutations were made in the wild-type Factor VII to increase its bioactivity. 18, 19 We predicted promiscuous binding regions in the mutated and wild-type factor VII sequences. From the immunogenic region (positions 291-310), several variants with decreased immunogenicity were predicted. For experimental validation, we selected 35 peptides that included 14 analogues with predicted reduced binding, along with seven neighbouring and four wild-type peptides. As controls, 10 analogues predicted with no decrease in HLA binding were included.
In vitro immunogenicity assays
We used donations of peripheral blood mononuclear cells (PBMCs) from five healthy adults from San Diego, CA. All donors provided written informed consent for participation in the study. This study was performed with approvals from the Institutional Review Board at the La Jolla Institute for Allergy and Immunology (protocols; VD-101-0513 and VD-059-0813). Peptides were purchased from A&A (San Diego, CA) as crude material on a small (1 mg) scale and resuspended in DMSO at a final concentration of 40 mg/m. The PBMCs were isolated by density gradient centrifugation, according to the manufacturer's instructions. Cells were cryopreserved in liquid nitrogen suspended in fetal bovine serum containing 10% (volume/volume) DMSO. Culturing of PBMCs for in vitro expansion was performed by incubating in RPMI-1640 (Omega Scientific, Tarzana, CA) supplemented with 5% human AB serum (Gemini Bioscience, Liverpool, UK), 1% GlutaMAX (Gibco, Grand Island, NY), and 1% penicillin/streptomycin (Omega Scientific) in 24-well plates at a density of 2 9 10 6 cells per well. Peptides were added to the cultures at a concentration of 50 lg/ml. Every 3-4 days, 10 U/ml IL-2 (eBioscience, San Diego, CA) in medium was added to the cultures.
After 14 days of culture with individual peptides, the cells were harvested and re-stimulated with the peptides at 5 lg/ ml in an interferon-c and IL-5 dual ELISPOT as previously described. 53 To be considered positive, a peptide response had to match three different criteria: elicit at least 320 spotforming cells per 10 6 PBMCs, stimulation index ≥ 2 and P ≤ 0Á05 by Student's t-test or by a Poisson distribution test.
Results
Equivalent performance of various prediction strategies on the two main immunogenic regions of EPO
A previous study evaluated the immunogenicity of EPO for human T cells in vitro, identifying two main immunogenic regions. 51 Modification of these regions was then shown to reduce immunogenicity of the whole protein. 51 In that study, it was further demonstrated how the two main immunogenic regions could be identified on the basis of measured promiscuous binding affinity to 15 common HLA molecules. Figure 1(a) shows the previously reported and published EPO immunogenicity. The EPO data from Tangri et al. were chosen as they are the only data set, to the best of our knowledge, in which analogues of the given protein designed for lower HLA binding have also been experimentally tested for immunogenicity. P1  P6  P11  P16  P21  P26  P31  P36  P41  P46  P51  P56  P61  P66  P71  P76  P81  P86  P91  P96  P101  P106  P111  P116  P121  P126  P131  P136  P141  P146 Herein, we wanted to evaluate several commonly available prediction methods for their capacity to identify these two main immunogenic regions. First, we used the 'IEDB-recommended' method 52 to predict the HLA-binding affinities of the various peptides for the same 15 alleles used in the EPO study above. Additionally, we evaluated the efficacy of predictions for a panel of 26 alleles most common in the general population, 41 and a recently described seven-allele subset (the '7-allele method' 50 ), for identifying the protein regions that are bmost immunogenic at the population level, as described in the Materials and methods.
To visualize the results of the various methods, Fig. 1(a) shows the 1/median centile predicted values for the 15 alleles originally used, the 7-allele method, and for the 26-allele panel, each overlaid to the published immunogenicity values. The dotted line in the figure highlights the 1/median value of 0Á05, which corresponds to a 20th centile median value, previously defined as a broad immunogenicity threshold for the general population. 37, 38, 45, 50 Receiver operating characteristics (ROC) plots provide a threshold-independent approach to compare the efficacy of different models. Based on the ROC curve, an AUC value can be calculated to express overall performance. 54 In this context, AUC values of 0Á5 represent random performance, whereas a value of 1 is a perfect prediction. ROC plots and associated AUC values for the median centile for the 7-, 15-and 26-allele methods are provided in Fig. 1(b) . From these results we concluded that the performance of the various methods is similar, with AUC values in the 0Á852-0Á861 range.
The nature of substitutions considered in deimmunization projects Previous studies 46 have reported different strategies to generate amino acid substitutions for the purpose of reducing immunogenicity (for recent studies see refs 2,5,9,10,55-57). In several studies, alanine replacements have been used (see refs 12,25,56,58,59) . The rationale for alanine replacement is that it is a relatively conservative or semi-conservative substitution for most amino acids, and as such is hypothesized to be less likely to interfere with the biological activity of the protein being considered. The potential drawback of using alanine is that the mild nature of the change might not impact HLA binding in a sufficiently decisive manner. An alternative approach, proposed by Tangri et al., 51 was to introduce non-conservative substitutions as a targeted strategy to interfere with HLA binding. Here, we review the published data to gain additional insights into these issues.
Previous studies by Stern et al. 60 solved the X-ray crystal structure of the influenza HA 307-319 epitope and HLA DR1 complexed to a T-cell receptor (TCR). It was determined that the peptide residues in positions 1, 4, 6 and 9 of a 9mer core (corresponding to residues 309, 312, 316 and 319 of the peptide) were the primary HLA contact residues, while À1, 3 and 8 were the main TCR contact residues.
Independent studies determined the HLA-binding capacity of HA 307-319 analogues to DR1. 61 As summarized in Fig. 2 , alanine substitutions only interfere with binding in position 1, but not any of the other three anchor positions (i.e. positions 4, 6 and 9). This is explained by the fact that alanine is a semi-conservative substitution for the native residues found in positions 4 (Q) and 9 (L), and is a conservative substitution for the T found in position 6 (an alanine substitution actually increases binding in this position). Conversely, by disrupting binding by more than 10-fold, non-conservative substitutions (K or E) correctly identify all four HLA contact residues. At the level of T-cell recognition, the effect of alanine substitutions on most positions was investigated by Alexander et al. 62 The results, also summarized in Fig. 2 , indicate that alanine substitutions abrogate T-cell recognition at all three main TCR contact residues. These findings were not limited to this particular HLA/epitope combination, as the same conclusions are reached by analysis of X-ray structures, binding and T-cell activation assays for the HA peptide in the context of DRB1*0401, 63, 64 and DRB1*0701 65 and of MBP 85-99 epitope in the context of HLA DRB1*15:01. 66 In conclusion, these results indicate that alanine substitutions are a feasible strategy to broadly interfere with TCR recognition. However, as HLA binding is retained in most instances, it is concerning that the analogue drug might elicit a new set of T cells with different TCR specificity. The data indicate that alanine substitutions are not a feasible strategy to broadly interfere with HLA binding, and non-conservative substitutions may be more suited to this purpose.
EPO analogues associated with reduced immunogenicity
The Tangri et al. study 51 described several single substitution replacements that were evaluated for their effect on immunogenicity. Here we tabulated these analogues (Table 1) , recording their sequence and effect on immunogenicity. We define, for the purpose of our analysis, reduced immunogenicity as an instance where the response was reduced by more than 50% in 50% or more donors.
Evaluation of the 26-allele method to predict analogues associated with decreased immunogenicity Next, we evaluated the capacity of the various methods described above to predict decreased immunogenicity in the Table 1 data set. For each method we recorded the number of true positives (TP), false positives (FP), false negatives (FN) and true negatives (TN). The MCC was also calculated for comparison between the different approaches tested. This measure is most appropriate when the data sets for validation are associated with binary outcomes (yes/no in terms of experimentally reduced immunogenicity and yes/no in terms of predictions). MCC can range from À1 to 1, where À1 indicates a perfect negative correlation, 0 means a random distribution and 1 indicates a perfect positive correlation. In general, MCC values of +0Á70 or higher indicate a very strong positive relationship, +0Á40 to +0Á69 a strong positive relationship, +0Á30 to +0Á39 a moderate positive relationship, and values of +0Á20 to +0Á29 indicate a weak positive relationship. 67 Preliminary analyses showed that the 26-allele method had a slightly better performance than the other methods. Accordingly, as criteria to predict decreased immunogenicity, in relative terms in comparison with the wildtype epitope, we considered the difference of the 26-allele median centile of a given analogue compared with the median for the wild-type sequence. The two EPO regions were evaluated separately or combined. Examining performance using different median value thresholds, a difference of 8Á5 was found to be optimal. This cut-off was empirically defined. The data in Table 2 were given to evaluate the performance of our prediction model in both the immunogenic regions of EPO. The performance was evaluated in terms of sensitivity, specificity, accuracy and MCC, with MCC values of 0Á5, 0Á5 and 0Á41 for Region 1, Region 2 and both regions combined. Based on these results we proceeded to implement an algorithm that, for any given analogue sequence, would automatically calculate the difference in the median of 26-allele method value between the wild-type potential epitope and the analogue in question, as described in more detail in the following sections.
A scheme to weigh the potential effect of introducing new epitopes in flanking regions Any de-immunization strategy must account not only for decreasing the HLA-binding capacity of the targeted epitope, but also avoid the unintended creation of new epitopes in neighbouring sequences. In this context, amino acid substitutions in a 15mer peptide can also affect a maximum of two-neighbouring peptides in a protein sequence (as we are considering sets of sequential 15mer peptides overlapping by 10 residues). In some cases, namely when a potential epitope is at the C-or Nterminus of a protein, only one neighbouring 15mer is found, whereas in the case of an isolated peptide, no neighbouring 15mer is found.
To evaluate the potential impact of creating other immunogenic regions in neighbouring peptides, we have adopted a scheme that also scores neighbouring 15mers (Table 3 ). In this arbitrary schema, a lower score is associated with a more preferred analogue, specifically one predicted to have no effect on neighbouring peptides, or to confer reduced immunogenicity. The arbitrary score varies in range from 1 to 10, where the lowest score (i.e. 1) is given to an analogue where no neighbouring peptide is present (i.e. 15mer peptide subjected to de-immunization), as by definition, no neighbouring peptide can be affected by the substitution. The next lowest score (2) is given to the 'next-best' scenario, namely, only one neighbouring peptide is present and the analogues of such neighbouring peptides (either C-or N-terminal peptides) were also predicted to have reduced immunogenicity, based on a lower median score in comparison with the wild-type peptide. The next score would be 3, corresponding to the case in which both neighbouring peptides are present and are predicted to be associated with reduced immunogenicity. The next lowest score of 4 is given to analogues where, out of two neighbouring peptides, one is either absent or is predicted with reduced immunogenicity, while the other has no change in immunogenicity, and so on. The highest score is assigned to analogues where additional immunogenic sites are created in the neighbouring region. This schema (Table 3) is utilized to rank and evaluate the results of the de-immunization predictions in the predictive tool described in the following sections.
Development of an interface for 26-allele method immunogenicity calculations
Overall, the de-immunization tool consists of a two-step process (Fig. 3) : (i) identification of immunogenic region and (ii) evaluation of all analogues to identify those with decreased binding affinity and that do not affect neighbouring peptides. To facilitate implementing this process in the context of a generally usable protein de-immunization tool, we first developed a web application (Fig. 4) that accepts the sequence of proteins or peptides and automatically generates as output the specific regions that are predicted to be dominant epitopes at the population level. Median values of the predicted 26-allele centile are also reported.
Accordingly, in the input module, the protein sequence is entered, and the user can select a threshold/cut-off value for determining predicted immunogenic regions in that protein (Fig. 4a) . A threshold value of 20% is used as the default, as it was previously defined as a broad immunogenicity threshold (derived in vitro) for the general population, 45 and also associated with optimal performance (in terms of MCC) in the case of data from the EPO study described above. However, the user can apply any threshold value that fits with their specific needs or context.
Our prediction strategy is based on fixed median values. We previously demonstrated that median values perform best in other immunogenicity predictions, 50, 52 whereas the use of other parameters such as means or minima might bias the selection in favour of single 'outlier' values. Alternative methods in addition to medians and fixed values could be implemented in future versions of the tool.
After user input is submitted, an intermediate page (Fig. 4b) displays the potentially immunogenic regions predicted by the 26-allele method, automatically parsing sequences into 15mer peptides overlapping by 10 residues. This interactive page allows for selection of one or more of the various predicted peptides (15mers) for further analysis, which automatically redirects to a subsequent results page.
In the case of the EPO sequence example, this page at the default setting returns eight peptides, including the Predicted immunogenicity of neighbouring peptide in the two erythropoietin regions was evaluated and categorized as Absent (when no neighbour peptide is present), Neutral (when neighbour peptide median score is the same of the wild-type), Reduced (when neighbour peptide median score is lower than that of the wild-type) or Increased (when neighbour peptide median score is higher than that of the wild-type). A ranking score was assigned based on the combination of the two regions. Lower scores correspond to more preferred analogues. 
Output screen for the de-immunization tool
The algorithm automatically calculates the difference in median percentile rank for the 26-allele 'IEDB-recommended' method value between the wild-type potential epitope and each of the possible 285 analogues (15 positions 9 19 possible substitutions). The results are summarized in tabular format, with the first row representing the wild-type peptide and the following rows representing the scores of the various analogues (Fig. 4c) . For each analogue peptide sequence the median centile rank, as well as the difference in centile rank between wild-type and analogue, is shown. The output also shows the effect of the substitutions on neighbouring peptides (columns CN1, CN2, NN1, NN2). These columns represent the (one/two) neighbouring peptide(s) at the C and N termini, respectively (Fig. 4c) . In the last column, a score that reflects the cumulative effect of the substitution on neighbouring peptides is also provided, where lower values are preferred for de-immunization. The summary table includes, by default, only analogues with a difference greater than 8Á5, but the user can select and opt for different thresholds (more or less stringent) (Fig. 4c) . The results are sorted according to the scheme shown in Table 3 , and then by median difference for the 26-allele method.
As noted above, the tool operates in a two-step manner. The first step is to identify immunogenic peptides, which is relatively quick (less than 5 seconds for a 15mer). The second step is to evaluate all the possible variants of each 15mer, along with their flanking peptides (285 variants for a 15mer peptide). This step, in its present implementation, takes around 9 minutes (550Á01 seconds to be exact). Considering the computational intensive nature of the calculation, we also offer to email the results to the user.
Immunogenic protein sequence
Step 2: Predict non-immunogenic variants of immunogenic peptides
Step 
Application of the de-immunization tool to select factor VII analogues with reduced immunogenicity
To illustrate the utility of the programme, we used the sequence of Vatreptacog a, an engineered factor VII molecule whose development was discontinued because of immunogenicity problems during human clinical testing. 68 In humans, the factor VII sequence is self, and hence largely non-immunogenic. However, the introduction of several mutations within the wild-type sequence to improve drug efficacy inadvertently rendered the drug immunogenic. 18, 19 When the Vatreptacog a sequence was run through the de-immunization tool, it was found that the 26-allele method predicted 10 peptides, corresponding to seven regions (as two contiguous peptides were predicted in the 196-215, 271-290 and 291-230 regions). Vatreptacog a was created with three mutations (V158D, E296V, M298Q) in the wild-type sequence. Out of these three mutations, two mutations were predicted to increase immunogenicity in the 291-310 region, spanning two of the predicted 15mers (position 291-305 and position 296-310) ( Table 4) . 69 The remaining six regions predicted to be immunogenic were identical to the wild-type factor VII sequence. Accordingly, we have chosen the 291-310 region for experimental validation. This region, and specifically the nested 291-305 peptide, was ranked first within the 10 predicted peptides with a median value of 6Á965. It must be noted, however, that not all predicted regions were immunogenic, probably because these other regions are 100% self, and so not recognized due to Tcell tolerance.
For further analyses, we selected two peptides (291-305 and 296-310) covering the predicted immunogenic region, and generated the list of analogues expected to be associated with reduced immunogenicity. In the case of peptide 291-305 we identified 32 different analogues that are predicted to be associated with reduced immunogenicity (Table 5A ). Of those, 13 represented substitution of L297, one of L296, two of Q298, seven of L300, eight of L305 and one for R304. In the case of peptide 296-310, 45 substitutions were predicted to have reduced immunogenicity (see Supplementary material, Table S1 ). These substitutions correspond to seven different positions (V297, V299, L300, N301, V302, R304, L305).
Scrutinizing the two sets we observed that 25 (see Supplementary material, Table S2 ) different substitutions were predicted to have detrimental effect for both predicted epitopes, and also to have favourable profiles in terms of neighbouring peptides (scored as a '3'; see Table 3 ). These 25 substitutions would therefore be predicted as the most promising for further testing. Four positions (L297, L300, R304 and L305) accounted for all 25 substitutions.
Experimental validation of the de-immunization tool's predictions
To experimentally validate the output of the de-immunization tool, we next synthesized and tested in in vitro Tcell immunization assays a panel of peptide analogues based on the 291-305 and 296-310 wild-type epitopes, and including the two neighbouring peptides (one Cterminal, one N-terminal) ( Table 5B ). The panel included analogues predicted to be associated with decreased immunogenicity for both epitopes. The set of analogues encompassed seven substitutions for each epitope, made at four different positions (297, 300, 304 and 305). In addition, for each of those seven substitutions, we synthesized seven neighbouring peptides, as only one neighbouring peptide is affected by each common substitution from the two selected 291-305 and 296-310 peptides. Finally, as controls, 10 peptides -representing five substitutions, each in the two different frames (291-305 and 296-310) -predicted (based on increased median affinity) to be associated with no decrease in immunogenicity were included.
All peptides were tested for immunogenicity with human PBMCs from five normal donors using a 2-week in vitro re-stimulation protocol, 53 followed by ELISPOT assays measuring the number of cells secreting interferonc or IL-5 in response to a 20-hr stimulation with each specific peptide. Given the small number of donors and peptides tested, compiled data are shown in Fig. 5(a, b) . The results for individual peptide data are provided in the Supplementary material (Table S3 ). In the case of control peptides, positive responses were detected in 46% of the cultures of those controls predicted to be immunogenic, but only in 21Á4% of the decreased immunogenicity analogues and 11Á4% of the flanking region controls (Fig. 5a ). When response magnitude is considered, the corresponding (geometric mean) responses were 704, 445 and 360 spot-forming cells, respectively (Fig. 5b) . Onetailed Mann-Whitney U-tests of control versus decreased immunogenicity analogues was associated with significant differences for both frequency and magnitude of response (Fig. 5a, b) . 166  180  10Á91  WQVLLLVNGAQLCGG  10Á91  WQVLLLVNGAQLCGG  181  195  11Á54  TLINTIWVVSAAHCF  11Á54  TLINTIWVVSAAHCF  196  210  12Á39  DKIKNWRNLIAVLGE  12Á39  DKIKNWRNLIAVLGE  201  215  15Á18  WRNLIAVLGEHDLSE  15Á18  WRNLIAVLGEHDLSE  241  255  9Á595  HDIALLRLHQPVVLT  9Á595  HDIALLRLHQPVVLT  271  285  15Á325  RTLAFVRFSLVSGWG  15Á325  RTLAFVRFSLVSGWG  276  290  17Á55  VRFSLVSGWGQLLDR  17Á55 Wild  GATALVLQVLNVPRL  6Á965  0  15Á75  40Á405  20Á815  40Á665  NA  L297P  GATALVPQVLNVPRL  29Á03  22Á065  29Á435  NA  23Á83  NA  3  L297G  GATALVGQVLNVPRL  25Á1  1 8 Á135  27Á95  NA  23Á7  N A  3  L297D  GATALVDQVLNVPRL  24Á91  17Á945  27Á255  NA  23Á08  NA  3  L297C  GATALVCQVLNVPRL  24Á585  17Á62  25Á09  NA  26Á23  NA  3  L297E  GATALVEQVLNVPRL  24Á11  17Á145  27Á09  NA  21Á56  NA  3  Q298P  GATALVLPVLNVPRL  21Á57  14Á605  21Á09  NA  21Á055  NA  3  L300C  GATALVLQVCNVPRL  19Á75  12Á785  34Á225  NA  22Á085  NA  3  Q298G  GATALVLGVLNVPRL  19Á33  12Á365  19Á14  NA  24Á805  NA  3  L305D  GATALVLQVLNVPRD  18Á515  11Á55  37Á665  65Á34  NA  NA  3  L297R  GATALVRQVLNVPRL  18Á29  11Á325  25Á43  NA  22Á115  NA  3  L297H  GATALVHQVLNVPRL  18Á155  11Á19  24Á295  NA  22Á655  NA  3  L305E  GATALVLQVLNVPRE  18Á115  11Á15  35Á605  63Á515  NA  NA  3  L297Q  GATALVQQVLNVPRL  17Á87  10Á905  24Á265  NA  22Á45  NA  3  L305C  GATALVLQVLNVPRC  17Á81  10Á845  35Á94  66Á38  NA  NA  3  L305P  GATALVLQVLNVPRP  17Á8  1 0 Á835  31Á08  65Á785  NA  NA  3  L297T  GATALVTQVLNVPRL  17Á69  10Á725  26Á78  NA  23Á695  NA  3  L297K  GATALVKQVLNVPRL  17Á48  10Á515  24Á235  NA  21Á955  NA  3  L300W  GATALVLQVWNVPRL  17Á39  10Á425  22Á125  NA  21Á93  NA  3  L297S  GATALVSQVLNVPRL  17Á365  10Á4  2 5 Á305  NA  21Á695  NA  3  L300R  GATALVLQVRNVPRL  17Á125  10Á16  26Á415  NA  21Á92  NA  3  L305G  GATALVLQVLNVPRG  16Á625  9Á66  33Á365  65Á88  NA  NA  3  L305N  GATALVLQVLNVPRN  16Á37  9Á405  32Á895  64Á735  NA  NA  3  L300H  GATALVLQVHNVPRL  16Á295  9Á33  29Á685  NA  21Á9  N A  3  L300G  GATALVLQVGNVPRL  16Á29  9Á325  31Á105  NA  22Á51  NA  3  L297N  GATALVNQVLNVPRL  16Á26  9Á295  24Á82  NA  22Á45  NA  3  L297A  GATALVAQVLNVPRL  16Á155  9Á19  25Á695  NA  21Á335  NA  3  L300K  GATALVLQVKNVPRL  15Á905  8Á94  20Á79  NA  21Á935  NA  3  L305W  GATALVLQVLNVPRW  15Á825  8Á86  23Á81  41Á925  NA  NA  3  L305Q  GATALVLQVLNVPRQ  15Á815  8Á85  29Á325  63Á305  NA  NA  3  V296P  GATALPLQVLNVPRL  15Á61  8Á645  18Á375  NA  24Á135  NA  3  L300P  GATALVLQVPNVPRL  15Á485  8Á52  40Á37  NA  21Á165  NA  3  R304G  GATALVLQVLNVPGL  15Á48  8Á515  24Á575  44Á165  NA 
Discussion
The present report represents, to the best of our knowledge, the first freely accessible method to automatically identify substitutions of potential value in terms of de-immunization of protein sequences, in general, and protein drugs in particular. The tool, available to the public through the IEDB's Analysis Resource (http://tools. iedb.org/deimmunization/), is designed to allow user flexibility, as different cut-offs can be selected, if the user wishes to deviate from the default settings. [70] [71] [72] Protein immunogenicity is of serious concern in the context of protein immunotherapeutics. 7 T cells are key players in determining protein immunogenicity, directly through hypersensitivity reactions, and indirectly through providing the T-cell help required for immunoglobulin switch and generation of high-affinity antibody responses through affinity maturation. There is a clear appreciation for the fact that T-cell immunogenicity is a multifactorial process. Main factors include protein availability and pharmacodynamics, protein uptake and processing from immune cells, binding to HLA molecules and recognition from a suitable repertoire of antigen-specific T cells. Although each of these factors can be targeted and modified for the purpose of decreasing immunogenicity, our approach specifically targets HLA-binding capacity. As such, we emphasize that our method is potentially complementary and synergistic with methodologies aimed at modulating other variables. Our approach is based on the notion that HLA-binding affinity is a key requisite for T-cell immunogenicity. Several studies indicate that HLA binding is necessary (albeit not sufficient) for T-cell immunogenicity, and in that respect, if HLA-binding activity is decreased or abolished, a corresponding decrease in immunogenicity is to be expected. 6 The validation studies that we report herein, also in the context of previous studies using EPO as a model system, demonstrate that this is indeed the case. 51 The purpose of this tool is to afford the capacity to predict immunogenicity at a population level, to include not only the DRB1 locus, but also accounting for DP and DQ loci as previously described in the 7-allele method. 50 The tool is not designed to predict immunogenicity of a specific allele, for which purpose a completely different strategy involving testing HLA-matched donors and using HLA-specific predictions would be recommended. To ensure broader HLA allele coverage, we selected the 26-allele method 41 instead of the 7-allele method, as they have shown equivalent performance. Importantly, we find that the best substitutions to significantly reduce HLAbinding capacity are in general non-conservative substitutions. This is in agreement with the bulk of immunochemical knowledge, which demonstrates that conservative substitutions are unlikely to significantly affect binding, even if introduced at key anchor positions. This has relevance in terms of the potential use of these substitutions, and additional experimental tests and/or structural simulations are required to select which of these substitutions is compatible with retaining protein function and drug potency.
Other de-immunization studies also based on introducing single amino acid substitutions into known epitopes have been reported in the literature (see, for example, refs 2,5,9,10,12,25,55-59, as cited above). In those studies, mild and conservative substitution strategies, such as 'alanine scans', were shown to be effective. These types of conservative substitutions are probably effective due to interference with TCR recognition (and have been routinely used to map TCR contact residues). At the same time, however, and as shown in Fig. 2 , because conservative substitutions do not reliably and significantly interfere with MHC binding, they are subsequently vulnerable to the elicitation of a new set of T cells. By contrast, our approach takes into consideration non-conservative substitutions that are able to disrupt both HLA binding and TCR recognition.
At the same time, it is possible that whereas conservative substitution strategies may elicit a new wave of T cells that recognize a different set of TCR accessible residues on the same epitope region, they may have an important advantage of being less likely to perturb protein function. Further, it is also possible that the use of 'low profile' substitutions, such as alanine, might alleviate this problem, as it was shown that HLA class II restricted T cells often focus on large and charged amino acid side chains.
It is important to emphasize that modification of HLA-binding capacity does not address the central issue of T-cell tolerance. T cells are in general tolerant or non-reactive to self-protein sequences, and therefore any modification of self-protein sequences can lead to increases in immunogenicity because the molecule is perceived as non-self and promptly recognized by the immune scrutiny. In this light, protein modification of totally self-molecules should be used judiciously, and determinations of self/non-self status should be pursued in parallel. This is a key feature of our approach as it provides an actionable strategy that can be implemented in the general population. Algorithms exist to predict binding capacity for several hundred different allelic variants expressed at different loci, but to search for substitutions simultaneously affecting such large numbers of alleles is not practical. Further, the impact of different substitutions must be envisioned at a global population level. Several previous studies in single-allele or genetically inbred animal models have provided evidence to support the concept that reduced binding can confer reduced immunogenicity. What is required, however, is the ability to 'jump' to human patient populations associated with a large degree of heterogeneity, in general, and at the level of HLA class II in particular. Previous studies have defined sets of alleles that are representative of HLA diversity on the one hand, and the extensive repertoire convergence existing at the level of peptide-binding specificity of HLA class II molecules on the other. 41 Our approach provides a strategy to identify candidate amino acid substitutions for decreased immunogenicity, globally applicable to heterogeneous populations. directed the study and wrote the manuscript. All authors have critically read and edited the manuscript.
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